Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Roel Funke"'
Autor:
Jeffrey J. Wallin, Johanna C. Bendell, Roel Funke, Mario Sznol, Konstanty Korski, Suzanne Jones, Genevive Hernandez, James Mier, Xian He, F. Stephen Hodi, Mitchell Denker, Vincent Leveque, Marta Cañamero, Galina Babitski, Hartmut Koeppen, James Ziai, Neeraj Sharma, Fabien Gaire, Daniel S. Chen, Daniel Waterkamp, Priti S. Hegde, David F. McDermott
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-8 (2016)
Cancer immunotherapy can be used in combination with other therapies for a better response. Here, the authors conduct a phase Ib clinical study and report the clinical activity and the immune response of the anti-PDL1 agent, atezolizumab, in combinat
Externí odkaz:
https://doaj.org/article/6805535216ff4aaca60ddedaf5252687
Autor:
Susan P. Foy, Kyle Jacoby, Daniela A. Bota, Theresa Hunter, Zheng Pan, Eric Stawiski, Yan Ma, William Lu, Songming Peng, Clifford L. Wang, Benjamin Yuen, Olivier Dalmas, Katharine Heeringa, Barbara Sennino, Andy Conroy, Michael T. Bethune, Ines Mende, William White, Monica Kukreja, Swetha Gunturu, Emily Humphrey, Adeel Hussaini, Duo An, Adam J. Litterman, Boi Bryant Quach, Alphonsus H. C. Ng, Yue Lu, Chad Smith, Katie M. Campbell, Daniel Anaya, Lindsey Skrdlant, Eva Yi-Hsuan Huang, Ventura Mendoza, Jyoti Mathur, Luke Dengler, Bhamini Purandare, Robert Moot, Michael C. Yi, Roel Funke, Alison Sibley, Todd Stallings-Schmitt, David Y. Oh, Bartosz Chmielowski, Mehrdad Abedi, Yuan Yuan, Jeffrey A. Sosman, Sylvia M. Lee, Adam J. Schoenfeld, David Baltimore, James R. Heath, Alex Franzusoff, Antoni Ribas, Arati V. Rao, Stefanie J. Mandl
Publikováno v:
Nature, vol 615, iss 7953
T cell receptors (TCRs) enable T cells to specifically recognize mutations in cancer cells1–3. Here we developed a clinical-grade approach based on CRISPR–Cas9 non-viral precision genome-editing to simultaneously knockout the two endogenous TCR g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd691b6fa2cf73c26cc536f7201c6b0c
https://escholarship.org/uc/item/2g96s8v7
https://escholarship.org/uc/item/2g96s8v7
Autor:
Mélanie Desbois, Thierry Giffon, Poonam Yakkundi, Sivani Pandey, Rodnie Rosete, Daniel Machado, Marigold Manlusoc, Susan Calhoun, Tasnim Kothambawala, Jey Ananta, Kristina Koyama, Yuan Cao, Dean Ng, Tomas Miranda-Katz, Avneesh Saini, Abhinav Jain, Hongjun Yue, Yang Cai, Miho Oyasu, Liz Bogaert, Roel Funke, Genevive Hernandez, Denise Nagata, Maya Leabman, Eric Humke, Stephen Carroll, Beatrice Wang, Bruce Keyt, Angus Sinclair, Maya Kotturi
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef3337c969ab061ff5e16b462458bf94
https://doi.org/10.1136/jitc-2022-sitc2022.1215
https://doi.org/10.1136/jitc-2022-sitc2022.1215
Autor:
Thierry D. Giffon, Melanie Desbois, Poonam Yakkundi, Susan Calhoun, Keerthana Sekar, Carolyn Denson, Tasnim Kothambawala, Alexander Pearson, Sivani Pandey, Deepal Pandya, Rodnie Rosete, Daniel Machado, Pat Raichlen, Dean Ng, Abhinav R. Jain, Roel Funke, Eric Humke, Paul R. Hinton, Beatrice Wang, Bruce A. Keyt, Maya F. Kotturi, Angus M. Sinclair
Publikováno v:
Cancer Research. 83:5660-5660
Immunostimulatory cytokines are a promising immunotherapy for the treatment of advanced malignancies, but generally have been associated with severe toxicities when administered systemically. The recent development of antibody-cytokine fusion protein
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ba347862003d19d9ed4bb9499b53020
https://doi.org/10.1158/1538-7445.am2023-5660
https://doi.org/10.1158/1538-7445.am2023-5660
Autor:
Sherene Loi, S.Y. Chui, Marina Nechaeva, Andreas Schneeweiss, A Nguyen Duc, Roel Funke, Amreen Husain, EP Winer, H. Iwata, Leisha A. Emens, Peter Schmid, HS Rugo, Véronique Diéras, Luciana Molinero, Sylvia Adams, Carlos Barrios
Publikováno v:
Cancer Research. 79:GS1-04
Background: The Phase III IMpassion130 study (NCT02425891) evaluated atezolizumab (anti–PD-L1) + nab-paclitaxel (nabPx) vs placebo + nabPx as first-line treatment for pts with metastatic triple-negative breast cancer (TNBC). The study met its co-pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::67993d943e5659b43a73239828071ee4
https://doi.org/10.1158/1538-7445.sabcs18-gs1-04
https://doi.org/10.1158/1538-7445.sabcs18-gs1-04
Autor:
Peter Schmid, Sylvia Adams, Hope S. Rugo, Andreas Schneeweiss, Carlos H. Barrios, Hiroji Iwata, Véronique Diéras, Roberto Hegg, Seock-Ah Im, Gail Shaw Wright, Volkmar Henschel, Luciana Molinero, Stephen Y. Chui, Roel Funke, Amreen Husain, Eric P. Winer, Sherene Loi, Leisha A. Emens
Publikováno v:
New England Journal of Medicine. 379:2108-2121
Unresectable locally advanced or metastatic triple-negative (hormone-receptor-negative and human epidermal growth factor receptor 2 [HER2]-negative) breast cancer is an aggressive disease with poor outcomes. Nanoparticle albumin-bound (nab)-paclitaxe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4e6c9e53fd1dec126c06f8abf95f2b8
https://doi.org/10.1056/nejmoa1809615
https://doi.org/10.1056/nejmoa1809615
Autor:
Luc Dirix, Jamie E. Chaft, Scott N. Gettinger, Marcin Kowanetz, Bo H. Chao, Rodney J. Hicks, Laura Q.M. Chow, Naiyer A. Rizvi, David R. Spigel, Jill Fredrickson, Alan Sandler, Larry Leon, Roel Funke, Peter Schmid
Publikováno v:
J Thorac Oncol
Introduction The FIR phase II study (NCT01846416) evaluated the efficacy and safety of anti–programmed death-ligand 1 (PD-L1) atezolizumab in advanced NSCLC selected by tumor cell (TC) or tumor-infiltrating immune cell (IC) PD-L1 expression. Method
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74f424b9608050bff5b3735231a91456
https://doi.org/10.1016/j.jtho.2018.05.004
https://doi.org/10.1016/j.jtho.2018.05.004
Autor:
Scott N. Gettinger, Paul Foster, D. Ross Camidge, Daniel Waterkamp, F. Stephen Hodi, Stephen V. Liu, Koho Iizuka, Rebecca S. Heist, Wei Zhang, John D. Powderly, Jeffrey Wallin, Neal Ready, Roel Funke, Giuseppe Giaccone
Publikováno v:
European Journal of Cancer. 101:114-122
Background Before the availability of immunotherapy, chemotherapy was standard first-line therapy for non–small-cell lung cancer (NSCLC) lacking actionable gene alterations. Preclinical evidence suggests chemotherapy is immunomodulatory, supporting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ba82ad0c8c9e1ab6f9cf1c29cc40da2
https://doi.org/10.1016/j.ejca.2018.06.033
https://doi.org/10.1016/j.ejca.2018.06.033
Autor:
David Y. Oh, Daniela A. Bota, Roel Funke, Mihaela C. Cristea, Mehrdad Abedi, Bartosz Chmielowski
Publikováno v:
Cancer Research, vol 81, iss 13_Supplement
Introduction: Broad application of neoTCR-T cell therapy involves isolation of mutation-targeted CD8 T cells from the blood of patients with different tumor types. An ultra-sensitive process streamlined for high-throughput capture of neoE-specific T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6af9561290edd85b8d9e193010cfd950
https://doi.org/10.1158/1538-7445.am2021-331
https://doi.org/10.1158/1538-7445.am2021-331
Autor:
Roel Funke, Bo Liu, Paula R. Pohlmann, Erika Hamilton, Daniel Waterkamp, Sara M. Tolaney, Jennifer R. Diamond, Luciana Molinero, Sylvia Adams, John D. Powderly, Wei Zou
Publikováno v:
Cancer Research. 76:P2-11
Background: Metastatic triple-negative breast cancer (mTNBC) is associated with poor prognosis, and chemotherapy remains the mainstay of treatment. Cancer immunotherapy represents a promising treatment approach for mTNBC, which is characterized by a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a11870513333bf492f1f5655fd9a8593
https://doi.org/10.1158/1538-7445.sabcs15-p2-11-06
https://doi.org/10.1158/1538-7445.sabcs15-p2-11-06